Tenaya Therapeutics is a clinical-stage biotechnology company focused on developing therapies that address the underlying causes of heart disease. Founded by leading cardiovascular scientists, Tenaya aims to revolutionize heart disease treatment through three interrelated platforms: Gene Therapy, Cellular Regeneration, and Precision Medicine. 

The company's gene therapy programs include TN-201 and TN-401, targeting genetic cardiomyopathies. TN-201 is designed to treat hypertrophic cardiomyopathy (HCM) associated with mutations in the MYBPC3 gene, while TN-401 aims to address arrhythmogenic right ventricular cardiomyopathy (ARVC) linked to PKP2 gene mutations. Both therapies utilize adeno-associated virus (AAV) vectors to deliver functional copies of these genes to heart muscle cells, potentially halting or reversing disease progression.